Immunomodulation by thalidomide and thalidomide analogues

Annals of the Rheumatic Diseases

Volumn 58, Issue SUPPL. 1, 1999, Pages

  Corral, Laura G ^a,b   Kaplan, Gilla ^b  

^a CELGENE CORPORATION   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0032726481     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.2008.i107     Document Type: Review

References (79)

1. Elkon K. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc Natl Acad Sci USA 1997;94:9814-19.
2. Nashleanas M, Kanaly S, Scott P. Control of Leishmania major infection in mice lacking TNF receptors. J Immunol 1998;160:5506-13
3. O'Brien D. Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun 1999;67:595-601.
4. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-72.
5. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-40.
6. Waage A, Steinshamn S. Cytokine mediators of septic infections in the normal and granulocytopenic host. Eur J Haematol 1993;50:243-9.
7. Tracey KJ, Cerami A. Tumor necrosis factor and regulation of metabolism in infection: role of systemic versus tissue levels. Proc Soc Exp Biol Med 1992;200:233-9.
8. Maini RN, Elliott MJ, Brennan FM, Feldmann M. Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA) [published erratum appears in Clin Exp Immunol 1995;102:443]. Clin Exp Immunol 1995;101:207-12.
9. Hawkey CJ, Stack WA. Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease [letter]. N Engl J Med 1998;338:333-4.
10. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8.
11. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168: 408-14.
12. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-97.
13. Fenner H. [TNF inhibitors: a new therapeutic perspective in chronic inflammatory diseases in rheumatology?]. Z Rheumatol 1995;54:158-64.
14. Tsenova L, Sokol K, Freedman VH, Kaplan G. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis 1998;177:1563-72.
15. Moreira AL, Wang J, Sarno EN, Kaplan G. Thalidomide protects mice against LPS-induced shock. Braz J Med Biol Res 1997;30:1199-207.
16. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.
17. Corral LG, Muller GW, Moreira AL, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996;2:506-15.
18. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
19. Moreira AL, Corral LG, Ye W, et al. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses 1997;13:857-63.
20. Marriott JB, Westby M, Cookson S, et al. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol 1998;161:4236-43.
21. Muller JM, Ziegler-Heitbrock HW, Baeuerle PA. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology 1993;187:233-56.
22. Bachelerie F, Alcami J, Arenzana-Seisdedos F, Virelizier JL. HIV enhancer activity perpetuated by NF-kappa B induction on infection of monocytes. Nature 1991;350:709-12.
23. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187:1885-92.
24. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7: 445-80.
25. Corral LG, Haslett PAJ, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs which are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6.
26. Haslett PAJ, Klausner JD, Makonkawkeyoon S, et al. Thalidomide stimulates T cell responses and interleukin-12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999;15:1169-79.
27. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993;177:925-35.
28. DeKruyff RH, Gieni RS, Umetsu DT. Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40. J Immunol 1997;158: 359-66.
29. Hollenbaugh D, Ochs HD, Noelle RJ, Ledbetter JA, Aruffo A. The role of CD40 and its ligand in the regulation of the immune response. Immunol Rev 1994;138:23-37.
30. Buhlmann JE, Gonzalez M, Ginther B, et al. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol 1999;162:4373-6.
31. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type I and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11: 247-57.
32. Schuler U, Ehninger G. Thalidomide: rationale for renewed use in immunological disorders. Drug Saf 1995;12:364-9.
33. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group [see comments]. N Engl J Med 1997;336:1487-93.
34. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease [see comments]. N Engl J Med 1992;326:1055-8.
35. Castilla EE, Ashton-Prolla P, Barreda-Mejia E, et al. Thalidomide, a current teratogen in South America. Teratology 1996;54:273-7.
36. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969-79.
37. Gunzler V. Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations. Drug Saf 1992;7:116-34.
38. Muller GW, Corral LG, Shire MG, et al. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996;39:3238-40.
39. Muller GW, Shire MG, Wong LM, et al. Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett 1998;8: 2669-74.
40. Muller GW, Chen R, Huang S-Y, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999;9:1625-30.
41. Oliver SJ, Freeman SL, Corral LG, Ocampo C, Kaplan G. Thalidomide analog CC1069 inhibits development of rat adjuvant arthritis. Clin Exp Immunol (in press).
42. Verghese MW, McConnell RT, Lenhard JM, Hamacher L, Jin SL. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol Pharmacol 1995;47:1164-71.
43. Verghese MW, McConnell RT, Strickland AB, et al. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther 1995;272: 1313-20.
44. Gantner F, Kusters S, Wendel A, Hatzelmann A, Schudt C, Tiegs G. Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors. J Pharmacol Exp Ther 1997;280:53-60.
45. Tamir A, Granot Y, Isakov N. Inhibition of T lymphocyte activation by cAMP is associated with down- regulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-Jun N-terminal kinase. J Immunol 1996;157:1514-22.
46. Moller DR, Wysocka M, Greenlee BM, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997;159: 5157-61.
47. Takenaka H, Maruo S, Yamamoto N, et al. Regulation of T cell-dependent and -independent IL-12 production by the three Th2-type cytokines IL-10, IL-6, and IL-4. J Leukoc Biol 1997;61:80-7.
48. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-50.
49. Chao NJ, Parker PM, Niland JC, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 1996;2:86-92.
50. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9.
51. Harbinson PL, MacLeod D, Hawksworth R, et al. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997;10:1008-14.
52. Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti- inflammatory effects in atopic dermatitis. J Invest Dermatol 1996;107:51-6.
53. Sekut L, Yarnall D, Stimpson SA, et al. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol 1995;100:126-32.
54. De Brito FB, Souness JE, Warne PJ. Type 4 phosphodiesterase inhibitors and their potential in the treatment of inflammatory disease. Emerging Drugs 1997;2:247-68.
55. Torphy TJ. Phosphodiesterase Isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care 1998;157:351-70.
56. Carpenter DO, Briggs DB, Knox AP, Strominger N. Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides. J Neurophysiol 1988;59:358-69.
57. Chirmule N, McCloskey TW, Hu R, Kalyanaraman VS, Pahwa S. HIV gp120 inhibits T cell activation by interfering with expression of costimulatory molecules CD40 ligand and CD80 (B71). J Immunol 1995;155:917-24.
58. Chehimi J, Starr SF, Frank I, et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994;179:1361-6.
59. Clerici M, Lucey DR, Berzofsky JA, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993;262:1721-4.
60. Wilson CC, Olson WC, Tuting T, Rinaldo CR, Lotze MT, Storkus WJ. HIV-1-specific CTI, responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. J Immunol 1999;162:3070-8.
61. Belyakov IM, Ahlers JD, Brandwein BY, et al. The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J Clin Invest 1998;102: 2072-81.
62. Chougnet C, Thomas E, Landay AL, et al. CD40 ligand and IFN-gamma synergistically restore IL-12 production in HIV-infected patients. Eur J Immunol 1998;28:646-56.
63. Nakajima A, Kodama T, Morimoto S, et al. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol 1998;161:1901-7.
64. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
65. Coughlin CM, Salhany KE, Wysocka M, et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998;101:1441-52.
66. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998;55:1827-34.
67. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-8.
68. Joseph IB, Isaacs JT. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst 1998;90:1648-53.
69. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
70. Berenson JR, Bergsagel PL, Munshi N. Initiation and maintenance of multiple myeloma. Semin Hematol 1999;36:9-13.
71. Posavad CM, Koelle DM, Corey L. High frequency of CD8+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. J Virol 1996;70:8165-8.
72. Ferbas J. Perspectives on the rule of CD8+ cell suppressor factors and cytotoxic T lymphocytes during HIV infection. AIDS Res Hum Retroviruses 1998;14 (suppl 2):S153-60.
73. Gollob JA, Schnipper CP, Orsini E, et al. Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12. J Clin Invest 1998;102: 561-75.
74. Cavanagh LL, Barnetson RS, Basten A, Halliday GM. Dendritic epidermal T-cell involvement in induction of CD8+ T cell- mediated immunity against an ultraviolet radiation-induced skin tumor. Int J Cancer 1997;70:98-105.
75. Odeka EB, Miller V. Thalidomide in oral Crohn's disease refractory to conventional medical treatment. J Pediatr Gastroenterol Nutr 1997;25:250-1.
76. Waters MF, Laing AB, Ambikapathy A, Lennard-Jones JE. Treatment of ulcerative colitis with thalidomide. BMJ 1979;1:792.
77. Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. Lancet 1997;350:1445-6.
78. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997;349:521-4.
79. Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest 1990;86:1255-60.